AI assistant
Cocrystal Pharma, Inc. — Director's Dealing 2016
Mar 17, 2016
35066_dirs_2016-03-17_f0c6b9cd-cb7c-4544-aeb9-7e7729988b02.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2016-03-15
Reporting Person: FROST PHILLIP MD ET AL (N/A)
Reporting Person: Frost Gamma Investments Trust (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-03-15 | Common Stock | P | 2941177 | $0.51 | Acquired | 106500147 | Indirect |
Footnotes
F1: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.